[{"id":"c67cb0cc-4062-4cc7-ac4c-e0358ba638bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06986174","created_at":"2025-06-28T16:12:40.055Z","updated_at":"2025-06-28T16:12:40.055Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia","source_id_and_acronym":"NCT06986174","lead_sponsor":"Shayna Sarosiek, MD","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" TP53 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2025-05-22"},{"id":"6496b67a-0445-408d-84b5-b4ec4d9b149e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06846463","created_at":"2025-03-03T10:04:54.767Z","updated_at":"2025-03-03T10:04:54.767Z","phase":"Phase 2","brief_title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","source_id_and_acronym":"NCT06846463","lead_sponsor":"Virginia Commonwealth University","biomarkers":" BCL2 • NOTCH1 • MYD88 • CD79B • CD5","pipe":"","alterations":" ","tags":["BCL2 • NOTCH1 • MYD88 • CD79B • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/31/2029","primary_completion_date":" 07/31/2029","study_txt":" Completion: 07/31/2032","study_completion_date":" 07/31/2032","last_update_posted":"2025-02-26"},{"id":"d69d9e8b-481b-4b6a-a241-66952601f3da","acronym":"RITZ","url":"https://clinicaltrials.gov/study/NCT05735834","created_at":"2023-02-21T16:01:53.200Z","updated_at":"2025-02-25T14:03:19.754Z","phase":"Phase 3","brief_title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","source_id_and_acronym":"NCT05735834 - RITZ","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-19"},{"id":"a65eaf0b-f986-4662-a858-795fc0730939","acronym":"","url":"https://clinicaltrials.gov/study/NCT04273139","created_at":"2021-01-18T20:45:24.651Z","updated_at":"2025-02-25T15:43:52.361Z","phase":"Phase 2","brief_title":"Ibrutinib + Venetoclax in Untreated WM","source_id_and_acronym":"NCT04273139","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • MYD88","pipe":" | ","alterations":" MYD88 mutation","tags":["BCL2 • MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/09/2020","start_date":" 07/09/2020","primary_txt":" Primary completion: 06/06/2022","primary_completion_date":" 06/06/2022","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-11"},{"id":"1da2b0c6-165f-4d0a-a3e8-ec861405f022","acronym":"BGB-3111-402","url":"https://clinicaltrials.gov/study/NCT05640102","created_at":"2022-12-07T16:57:49.810Z","updated_at":"2025-02-25T17:02:16.646Z","phase":"","brief_title":"Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia","source_id_and_acronym":"NCT05640102 - BGB-3111-402","lead_sponsor":"BeiGene","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 mutation • MYD88 L265P • MYD88 wild-type","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation • MYD88 L265P • MYD88 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-03"},{"id":"dd7ff569-d80c-47b3-9966-fc0126c7d73b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04263480","created_at":"2021-01-18T20:43:06.789Z","updated_at":"2024-07-02T16:35:03.965Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT04263480","lead_sponsor":"Christian Buske","biomarkers":" CD20 • MYD88 • CXCR4","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • carfilzomib"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-05-14"},{"id":"50186f31-5ca5-4488-bd84-bf563991c783","acronym":"","url":"https://clinicaltrials.gov/study/NCT04438005","created_at":"2021-01-18T21:21:51.408Z","updated_at":"2024-07-02T16:35:04.228Z","phase":"Phase 2","brief_title":"A Study of ICP-022 in Patients With R/R DLBCL","source_id_and_acronym":"NCT04438005","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" MYD88 • CD79B","pipe":" | ","alterations":" MYD88 L265P","tags":["MYD88 • CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 05/07/2020","start_date":" 05/07/2020","primary_txt":" Primary completion: 11/05/2021","primary_completion_date":" 11/05/2021","study_txt":" Completion: 12/13/2021","study_completion_date":" 12/13/2021","last_update_posted":"2024-05-13"},{"id":"ee25e9e3-0db7-4fcb-a64c-11f94e17e205","acronym":"VIWA-1","url":"https://clinicaltrials.gov/study/NCT05099471","created_at":"2021-10-29T14:53:17.774Z","updated_at":"2024-07-02T16:35:04.092Z","phase":"Phase 2","brief_title":"Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT05099471 - VIWA-1","lead_sponsor":"University of Ulm","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" CXCR4 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2024-05-13"},{"id":"c81f0280-85de-45ec-aa26-8f5b43ba0005","acronym":"","url":"https://clinicaltrials.gov/study/NCT05734495","created_at":"2023-02-21T16:01:35.955Z","updated_at":"2024-07-02T16:35:10.696Z","phase":"Phase 2","brief_title":"Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia","source_id_and_acronym":"NCT05734495","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • MYD88","pipe":" | ","alterations":" MYD88 wild-type","tags":["BCL2 • MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/02/2023","start_date":" 05/02/2023","primary_txt":" Primary completion: 01/25/2029","primary_completion_date":" 01/25/2029","study_txt":" Completion: 01/25/2033","study_completion_date":" 01/25/2033","last_update_posted":"2024-04-09"},{"id":"bcba688d-ccf2-45b4-927a-b48dc238e7e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05596097","created_at":"2022-10-27T15:58:27.582Z","updated_at":"2024-07-02T16:36:01.746Z","phase":"Phase 2","brief_title":"Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission","source_id_and_acronym":"NCT05596097","lead_sponsor":"LanZhou University","biomarkers":" TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/30/2022","start_date":" 10/30/2022","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2022-10-27"},{"id":"a15f3c21-a490-40cc-93c8-4d2c83593905","acronym":"","url":"https://clinicaltrials.gov/study/NCT05290337","created_at":"2022-03-22T12:52:47.199Z","updated_at":"2024-07-02T16:36:15.000Z","phase":"Phase 2","brief_title":"ZR-CHOP in DLBCL With Specific Gene Abnormality","source_id_and_acronym":"NCT05290337","lead_sponsor":"Fudan University","biomarkers":" TP53 • MYC • MYD88 • CD79B","pipe":" | ","alterations":" TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation","tags":["TP53 • MYC • MYD88 • CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 01/04/2022","start_date":" 01/04/2022","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2022-03-22"},{"id":"15d7a52b-337d-4b37-8862-81c425e8dbd7","acronym":"WAL-KU","url":"https://clinicaltrials.gov/study/NCT02640287","created_at":"2021-01-18T12:50:33.419Z","updated_at":"2024-07-02T16:36:26.833Z","phase":"","brief_title":"Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT02640287 - WAL-KU","lead_sponsor":"Central Hospital, Nancy, France","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 mutation • MYD88 L265P","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation • MYD88 L265P"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2021-08-06"},{"id":"a86fead0-6d68-4e5e-8342-7224d15b5ca0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04994626","created_at":"2021-08-06T12:53:05.326Z","updated_at":"2024-07-02T16:36:26.846Z","phase":"Phase 2","brief_title":"Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies","source_id_and_acronym":"NCT04994626","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" CD20 • MYD88 • CD79B • CD79A","pipe":" | ","alterations":" CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation","tags":["CD20 • MYD88 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2021-08-06"},{"id":"562ebd23-82cd-46f6-9ef4-7d25eaa6ea36","acronym":"","url":"https://clinicaltrials.gov/study/NCT02400437","created_at":"2021-01-18T11:27:12.209Z","updated_at":"2025-02-25T14:57:11.344Z","phase":"Phase 2","brief_title":"Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia","source_id_and_acronym":"NCT02400437","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" MYD88 L265P • CXCR4 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P • CXCR4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Ninlaro (ixazomib)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2020-09-02"},{"id":"29c8844b-f23b-467c-9e51-a60fcb29db0d","acronym":"DigiWAL","url":"https://clinicaltrials.gov/study/NCT03952052","created_at":"2021-01-18T19:27:05.119Z","updated_at":"2024-07-02T16:36:42.594Z","phase":"","brief_title":"Detection of Recurrent Mutations in Waldenström's Disease","source_id_and_acronym":"NCT03952052 - DigiWAL","lead_sponsor":"Centre Henri Becquerel","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 L265P","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 01/14/2019","start_date":" 01/14/2019","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2020-07-30"},{"id":"006e2786-ec9f-435c-b1a8-55c1b4f1678e","acronym":"PROTEOM","url":"https://clinicaltrials.gov/study/NCT04183569","created_at":"2021-01-18T20:23:47.835Z","updated_at":"2024-07-02T16:36:45.526Z","phase":"","brief_title":"Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04183569 - PROTEOM","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1","pipe":" | ","alterations":" CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation","tags":["BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 32","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-04-29"},{"id":"4e3f0ddf-4f8e-474d-aded-a7678e71df1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02252146","created_at":"2021-01-18T10:34:26.083Z","updated_at":"2024-07-02T16:37:15.602Z","phase":"Phase 1/2","brief_title":"Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation","source_id_and_acronym":"NCT02252146","lead_sponsor":"Idera Pharmaceuticals, Inc.","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 L265P","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bazlitoran (IMO-8400)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-12-12"},{"id":"08338ec0-6078-48e0-bc33-7c4d40eba740","acronym":"MEL58","url":"https://clinicaltrials.gov/study/NCT01585350","created_at":"2021-01-18T06:45:23.070Z","updated_at":"2024-07-02T16:37:29.831Z","phase":"Phase 1","brief_title":"A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients","source_id_and_acronym":"NCT01585350 - MEL58","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5","pipe":"","alterations":" ","tags":["MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2016-08-12"}]